A Study of Abilify® Tablet(Aripiprazole) as an Adjunctive Treatment in the Bipolar Depression
Status:
Recruiting
Trial end date:
2024-11-01
Target enrollment:
Participant gender:
Summary
This is an 8-week, multicenter, randomized, double blind, placebo controlled study to
evaluate the efficacy and safety of aripiprazole as an adjunctive treatment with mood
stabilizer for the treatment of patients (outpatients or inpatients) with type I or II
bipolar disorder accompanied by major depressive episode, without any psychotropic features.
This study involves patients who are considered by the investigator not to have a proper
improvement, despite receiving a mood stabilizer (lithium or valproic acid) for a sufficient
(≥ 28 days) period of time during the current depressive episode.